Prescribe to prevent: Overdose prevention and naloxone rescue kits for prescribers and pharmacists

Journal of Addiction Medicine

Volumn 10, Issue 5, 2016, Pages 300-308

  Lim, Jamie K ^a   Bratberg, Jeffrey P ^b   Davis, Corey S ^c   Green, Traci C ^d   Walley, Alexander Y ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c Public Health Law Center   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Pain; Prescription drug abuse; Prevention; Public health; Substance abuse

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANXIETY DISORDER; CHRONIC PAIN; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; LEGAL ASPECT; MEDICAL DEVICE; NALOXONE RESCUE KIT; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; OPIOID-RELATED DISORDERS; STANDARDS;

DRUG OVERDOSE; DRUG PRESCRIPTIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACISTS;

EID: 84996590127     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000223     Document Type: Review

References (106)

1. Abood, R. Pharmacy Practice and the Law, 6th ed. Jones&Bartlett; 2010:223.
2. American Medical Association. It's about saving lives: increasing access to naloxone. Available at: http://www.ama-assn.org/ama/ama-wire/post/itssaving-lives-increasing-access-naloxone. Published June 29, 2015. Accessed July 12, 2015.
3. American Pharmacists' Association. APhA Policy: controlled substances and other medications with the potential for abuse and use of opioid reversal agents. Available at: http://www.pharmacist.com/policy/controlled-substances-and-other-medications-potential-abuse-and-use-opioid-reversalagents-2. Published 2014. Accessed July 12, 2015.
4. American Society of Addiction Medicine. Public policy statement on the use of naloxone for the prevention of drug overdose deaths. Chevy Chase, MD. Available at: http://www.asam.org/docs/default-source/publicy-policystatements/1naloxone-rev-8-14.pdf. Revised 2014. Accessed July 12, 2015.
5. Baca CT, Grant KJ. What heroin users tell us about overdose. J Addict Dis 2007;26:63-68.
6. Beletsky L, Ruthazer R, Macalino GE, et al. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health 2007;84:126-136.
7. Beletsky L. The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose. Am J Prev Med 2015;48:357-359.
8. Bell J, Mattick R, Hay A, et al. Methadone maintenance and drug-related crime. J Subst Abuse 1997;9:15-25.
9. Bennett AS, Bell A, Tomedi L, et al. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 2011;88:1020-1030.
10. Beuger M, Tommasello A, Schwartz R, et al. Clonidine use and abuse among methadone program applicants and patients. J Subst Abuse Treat 1998;15:589-593.
11. Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: A longitudinal national cohort study. Addiction 2012;107:393-399.
12. Burris S, Beletsky L, Castagna C, et al. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev 2009;1:273-339.
13. Cacioppo JT, Hughts ME, Waite LJ, et al. Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. Psychol Aging 2006;21:140-151.
14. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650-660.
15. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014;1-8.
16. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014;8:153-163.
17. Clause S, Fudin J, Mergner A, et al. Prescribing privileges among pharmacists in veterans affairs medical centers. Am J Health Syst Pharm 2001;58:1143-1145.
18. Clausen T, Waal H, Thoresen M, et al. Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009;104:1356-1362.
19. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158:1-9.
20. Dart RC, Surratt HL, Cicero JF, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241-248.
21. Dasgupta N, Creppage K, Austin A, et al. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend 2014;145: 238-241.
22. Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend 2015;157:112-120.
23. Davis CS,Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics 2013;41(Suppl 1):33-36.
24. Davis CS, Pierce M, Dasgupta N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011. Am J Public Health 2014a;104:1389-1395.
25. Davis CS, Southwell JK, Niehaus VR, et al. Emergency medical services naloxone access: A national systematic legal review. Acad Emerg Med 2014b;21:1173-1177.
26. Davis CS, Carr D, Southwell JK, et al. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health 2015a;105:1530-1537.
27. Davis CS, Walley AY, Bridger CM. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics 2015b;43(Suppl 1):19-22.
28. Doe-Simkins M, Walley AY, Epstein A, et al. Saved by the nose: bystanderadministered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788-791.
29. Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study. BMC Public Health 2014;14:297.
30. Dolan KA, Shearer J, White B, Zhou J, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, reincarceration and hepatitis C infection. Addiction 2005;100:820-828.
31. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152:85-92.
32. Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87:931-941.
33. Evzio. Kaléo Cares Patient Assistance Program. Available at: http://evzio.-com/hcp/patient-savings/kaleo-cares-patient-assistance.php. Accessed July 9, 2015.
34. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170-175.
35. Gray JA, Hagemeier NE. Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural appalachia. Arch Intern Med 2012;172:1186-1187.
36. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103:979-989.
37. Green TC, Bowman S, Davis C, et al. Discrepancies in addressing overdose prevention through prescription monitoring programs. Drug Alcohol Depend 2015a;153:355-358.
38. Green TC, Dauria EF, Bratberg J, et al. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J 2015b;12:25.
39. Inocencio TJ, Carroll NV, Read EJ, et al. The economic burden of opioidrelated poisoning in the United States. Pain Med 2013;14:1534-1547.
40. International Medications Systems Limited; 2015. Naloxone hydrochloride [package insert]. El Monte, CA.
41. Jann M, Kennedy WK, Lopez G. Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 2014;27:5-16.
42. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103.
43. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers: United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132:95-100.
44. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015;S0749-3797(15):00163-4.
45. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309:657-659.
46. Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths. MMWR Morb Mortal Wkly Rep 2014;63:881-885.
47. Kerr D, Kelly AM, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 2009;104: 2067-2074.
48. Kinner SA, Milloy M-J,Wood E, et al. Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. Addict Behav 2012;37:691-696.
49. Krupitsky E, Nunes EV, LingW, et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicenter randomised trial. Lancet 2011;377:1506-1513.
50. Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat 2006; 30:129-133.
51. Langendam MW, van Brussel GH, Coutinho RA, et al. The impact of harmreduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001;91:774-780.
52. LaRochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med 2015;175: 978-987.
53. Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015;132(18 Suppl 2):S501-S518.
54. Li G, Brady JE, Lang BH, et al. Prescription drug monitoring and drug overdose mortality. Injury Epidemiol 2014;1(9).
55. Lobmann R, Verthein U. Explaining the effectiveness of heroin-assisted treatment on crime reductions. Law Hum Behav 2009;33:83-95.
56. Lynch KL, Shapiro BJ, Coffa D, et al. Promethazine use among chronic pain patients. Drug Alcohol Depend 2015;150:92-97.
57. Madadi P, Hildebrandt D, Lauwers AE, et al. Characteristics of opioid-users whose death was related to opioid-toxicity: A population-based study in Ontario, Canada. PLoS One 2013;8:e60600.
58. Mars SG, Bourgois P, Karandinos G, et al. Every 'never' I ever said same true": transitions from opioid pills to heroin injecting. Int J Drug Policy 2014;25:257-266.
59. Massachusetts Department of Public Health Bureau of Substance Abuse Services. Overdose Education and Naloxone Distribution (OEND) Pilot Expansion. Boston, MA. Available at: http://www.mass.gov/eohhs/docs/dph/substance-abuse/opioid/fy-15-oend-pilot-expansion-report.pdf. Published 2015. Accessed July 13, 2015.
60. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;8:CD002209.
61. Mattick RP, Breen C, Kinber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207.
62. Maxwell S, Bigg D, Stanczykiewicz K, et al. Prescribing naloxone to actively injecting heroin users: A program to reduce heroin overdose deaths. J Addict Dis 2006;25:89-96.
63. Meyer M, Benvenuto A, Howard D, et al. Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome. J Addict Med 2012;6:124-130.
64. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004;164:1875-1882.
65. Modarai F, Mack K, Hicks P, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend 2013;132:81-86.
66. Moller LF, Matic S, van den Bergh BJ, et al. Acute drug-related mortality of people recently released from prisons. Public Health 2010;124:637-639.
67. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-1985.
68. O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law 2003;12:295-324.
69. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011;12:747-754.
70. Piper TM, Stancliff S, Rudenstine S, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use and Misuse 2008;43:858-870.
71. Pollini RA, McCall L, Mehta SH, et al. Response to overdose among injection drug users. Am J Prev Med 2006;31:261-264.
72. Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 1999;94:471-478.
73. Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths: United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2015;64:1-5.
74. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry 2006;63:102-109.
75. Schwartz RP, Gryczynski J, O'Grady. et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health 2013;103:917-922.
76. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: A pilot intervention study. J Urban Health 2005;82:303-311.
77. Shapiro BJ, Lynch KL, Tochinda T, et al. Promethazine misuse among methadone maintenance patients and community-based injection drug users. J Addict Med 2013;7:96-101.
78. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry 2015;172:487-488.
79. Soyka M, Trader A, Klotsche J, et al. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. J Forensic Sci 2012;57:1524-1530.
80. Sporer KA, Kral AH. Prescription naloxone: A novel approach to heroin overdose prevention. Ann Emerg Med 2007;49:172-177.
81. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003;326:959-960.
82. Substance Abuse and Mental Health Services Administration. Results from the 2010 Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Center for Behavioral Health Statistics and Quality. Available at: http://www.samhsa.gov/data/sites/default/files/NSDUHNationalFindingsResults2010-web/2k10ResultsRev/NSDUHresults-Rev2010.pdf. Published 2011. Accessed June 22, 2015.
83. Substance Abuse and Mental Health Services Administration. "Opioid Overdose Prevention Toolkit." Rockville, MD. Available at: http://store.samhsa.gov/shin/content//SMA14-4742/Overdose-Toolkit.pdf. Revised 2014. Accessed July 12, 2015.
84. Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. Addiction 2005;100:397-404.
85. Tobin KE, Sherman SG, Beilenson P, et al. Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Intl J Drug Policy 2009;20:131-136.
86. U.S. Centers for Disease Control and Prevention. Multiple causes of death, 1993-2013 query. Available at: http://wonder.cdc.gov/mcd-icd10.html. Accessed June 22, 2015a.
87. U.S. Centers for Disease Control and Prevention. Deaths from Prescription Overdose. Available at: http://www.cdc.gov/drugoverdose/data/overdose.html. Published April 30, 2015b. Accessed July 6, 2015.
88. U.S. Centers for Disease Control and Prevention. Increases in Fentanyl Drug Confiscation and Fentanyl-related Overdose Fatalities. Available at: http://emergency.cdc.gov/han/han00384.asp. Published October 26, 2015c. Accessed December 11, 2015.
89. U.S. Department of Health and Human Services. Special General Memorandum 96-2: Designation of Pharmacists as Primary Care Providers with Prescriptive Authority. Available at: http://www.ihs.gov/IHM/index.-cfm?module=dsp-ihm-sgm-main&sgm=ihm-sgm-9602. Published October 18, 1996. Accessed July 27, 2015.
90. U.S. Department of Health and Human Services. Opioid Abuse in the U.S. and HHS Actions to Address Opioid-Drug Related Overdoses and Deaths. Available at: http://aspe.hhs.gov/sp/reports/2015/OpioidInitiative/ib-OpioidInitiative.cfm. Published March 26, 2015. Accessed July 10, 2015
91. U.S. Drug Enforcement Administration. Final Rule on Disposal of Controlled Substances. Available at: https://www.federalregister.gov/articles/2014/09/09/2014-20926/disposal-of-controlled-substances. Published Septebmer 9, 2014. Accessed June 22, 2015.
92. U.S. Drug Enforcement Administration. National Take-Back Initiative. Available at: http://www.deadiversion.usdoj.gov/drug-disposal/takeback/. Published 2015. Accessed June 22, 2015.
93. U.S. Food and Drug Administration. FDA Commissioner Margaret A. Hamburg Statement on Prescription Opioid Abuse. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391590.htm. Published April 3, 2014. Accessed July 6, 2015.
94. U.S. Food and Drug Administration. FDA moves quickly to approve easy-touse nasal spray to treat opioid overdose. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm. Published November 18, 2015. Accessed December 12, 2015.
95. U.S. Food and Drug Administration. FDA's Efforts to Address the Misuse and Abuse of Opioids. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337852.htm. Published February 6, 2013. Accessed August 13, 2015.
96. United Nations Office on Drugs and Crime.World Drug Report 2014. Vienna, Austria. Available at: http://www.unodc.org/documents/wdr2014/World-Drug-Report-2014-web.pdf. Published 2014. Accessed July 12, 2015.
97. Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Intl J Drug Policy 2010;21:186-193.
98. Walley AY, Doe-Simkins M, Quinn E, et al. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 2013a;44:241-247.
99. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013b;346:f174.
100. Wheeler E, Davidson PJ, Jones TS, et al. Community-based opioid overdose prevention programs providing naloxone: United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:101-105.
101. Wheeler E, Jones TS, Gilbert M, et al. Opioid overdose prevention programs providing naloxone to laypersons. MMWR Morb Mortal Wkly Rep 2015;64:631-635.
102. White JM, Irvine RJ. Mechanism of fatal opioid overdose. Addiction 1999;94:961-972.
103. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87:982-990.
104. Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Drug Monit 2002;24:457-470.
105. World Health Organization. Community management of opioid overdose. Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816-eng.pdf?ua=1&ua=1. Published 2014. Accessed July 12, 2015.
106. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioidrelated toxicity or overdose among Veterans Health Administration patients. Pain Med 2014;15:1911-1929.